Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN V POTASSIUM versus PENICILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN V POTASSIUM versus PENICILLIN VK.
PENICILLIN V POTASSIUM vs PENICILLIN-VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and activating autolytic enzymes.
Penicillin VK inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg orally every 6-8 hours.
250-500 mg orally every 6-8 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections (e.g., streptococcal pharyngitis, skin infections).
None Documented
None Documented
0.5-1 hour in patients with normal renal function; prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min). Clinical context: requires frequent dosing due to short half-life.
0.5 hours (normal renal function); prolonged to 3-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal excretion of unchanged drug accounts for 20-40% of the dose via glomerular filtration and tubular secretion; biliary excretion is minor (<1%). Fecal elimination is negligible.
Renal: 20-40% unchanged via tubular secretion; hepatic metabolism to penicilloic acid; biliary/fecal: minimal (<5%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic